Scarica l'app Stockscreener
58.06
4.76%
2.7463
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Bio Techne Corp Borsa (TECH) Ultime notizie
What analysts say about Bio Techne Corporation stockTriple returns potential - jammulinksnews.com
Bio Techne Corporation Stock Analysis and ForecastFree Investment Community - Autocar Professional
Bio-Techne Corporation shares rise 1.99% after-hours as US stocks close higher. - AInvest
Bio-Techne Corp. stock underperforms Monday when compared to competitors - MarketWatch
Envestnet Asset Management Inc. Sells 66,478 Shares of Bio-Techne Corp (NASDAQ:TECH) - Defense World
Bio-Techne’s Quarterly Earnings Preview: What You Need to Know - inkl
Bio-Techne’s Quarterly Earnings Preview: What You Need To Know - Barchart.com
Bio-Techne Schedules Q4 2025 Earnings Call: Full Fiscal Year Results Coming August 6 - Stock Titan
Bio-Techne to distribute Spear Bio’s ultrasensitive immunoassays - Yahoo Finance
Bio-Techne Corp (NASDAQ:TECH) Stake Lessened by M&T Bank Corp - Defense World
Analysts Set Bio-Techne Corp (NASDAQ:TECH) Price Target at $70.00 - Defense World
Why Bio Techne Corporation stock attracts strong analyst attentionProfitable Yet Secure Picks - Newser
How Bio Techne Corporation stock performs during market volatilityFree Expert-Led Investment Training - Newser
What makes Bio Techne Corporation stock price move sharplyOptimized Return Investment Picks - Newser
Here’s Headwaters Capital Management’s Investment Thesis for Bio-Techne (TECH) - Yahoo Finance
Spear Bio partners with Bio-Techne to expand ultrasensitive assay access By Investing.com - Investing.com South Africa
Spear Bio partners with Bio-Techne to expand ultrasensitive assay access - Investing.com
Bio-Techne Secures 1000x More Sensitive Biomarker Detection Technology in Major Neuroscience Partnership - Stock Titan
Bio-Techne (TECH) Partners with Spear Bio for Advanced Biomarker Detection | TECH Stock News - GuruFocus
Revolutionary Alzheimer's Biomarker Detection: Bio-Techne's New Platform Achieves 1000x Higher Sensitivity - Stock Titan
Bio-techne’s technology supports FDA approval of rare skin disorder therapy - Investing.com
Bio-Techne's Simple Western Enables Breakthrough FDA Approval for Rare Skin Disease Gene Therapy - Stock Titan
Teacher Retirement System of Texas Makes New Investment in Bio-Techne Corp (NASDAQ:TECH) - Defense World
Bio-Techne Corp (NASDAQ:TECH) Shares Sold by Principal Financial Group Inc. - Defense World
Teacher Retirement System of Texas Acquires New Holdings in Bio-Techne Corp (NASDAQ:TECH) - Defense World
Scotiabank Has Lowered Expectations for Bio-Techne (NASDAQ:TECH) Stock Price - Defense World
Scotiabank Maintains Buy Rating for Bio-Techne with $75 Price Target - AInvest
Bio-Techne stock price target lowered to $75 by Scotiabank - Investing.com Canada
TD Cowen Begins Coverage on Bio-Techne (NASDAQ:TECH) - Defense World
Minnesota's highest-paid CEOs made 7% more, with highest paid making $59.4M - Star Tribune
Assessing Bio-Techne: Insights From 7 Financial Analysts - Benzinga
Bio-Techne (TECH) Receives Buy Rating with $65 Price Target from TD Cowen | TECH Stock News - GuruFocus
Bio-Techne (TECH): TD Cowen Initiates Coverage with Buy Rating | - GuruFocus
Vontobel Holding Ltd. Decreases Stake in Bio-Techne Corp (NASDAQ:TECH) - Defense World
5 Revealing Analyst Questions From Bio-Techne’s Q1 Earnings Call - Yahoo Finance
Bio-Techne Corp. stock outperforms competitors on strong trading day - MarketWatch
GAMMA Investing LLC Cuts Stake in Bio-Techne Corp (NASDAQ:TECH) - Defense World
Amalgamated Bank Purchases 222 Shares of Bio-Techne Corp (NASDAQ:TECH) - Defense World
Is There Now An Opportunity In Bio-Techne Corporation (NASDAQ:TECH)? - Yahoo Finance
How To Trade (TECH) - news.stocktradersdaily.com
Janney Montgomery Scott LLC Grows Stake in Bio-Techne Corp (NASDAQ:TECH) - Defense World
Bio-Techne's New USP Deal on mAb and Gene Therapy May Boost Its Stock - Yahoo Finance
Bio-Techne stock holds steady as Stifel maintains $60 price target - Investing.com
Bio-Techne, USP Partner to Enhance Monoclonal Antibody, Gene Therapy Development - Insider Monkey
Major Breakthrough: Bio-Techne and USP Join Forces to Transform Gene Therapy Development Process - Stock Titan
First Week of August 15th Options Trading For Bio-Techne (TECH) - Nasdaq
Bio-Techne (NASDAQ:TECH) stock performance lags Nasdaq Composite in recent years - Kalkine Media
Bio-Techne Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
How the (TECH) price action is used to our Advantage - news.stocktradersdaily.com
Bio-Techne Director Cashes Out in Significant Stock Sale - TipRanks
Bio-Techne at Goldman Sachs Conference: Strategic Growth Amid Challenges - Investing.com
TECH Q1 Earnings Call: Management Highlights Market Uncertainties and Strategic Mitigation Efforts - Yahoo Finance
Transcript : Bio-Techne Corporation Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 10 - MarketScreener
Bio-Techne To Present At Goldman Sachs Global Healthcare Conference; Webcast At 10:40 AM ET - Nasdaq
ScaleReady Announces a G-Rex® Grant has been awarded to Immuneel Therapeutics - Yahoo Finance
Bio-Techne (TECH) Maintains 'Buy' Rating with $75 Price Target | TECH Stock News - GuruFocus
Benchmark maintains Buy rating on Bio-Techne stock amid tariff impact By Investing.com - Investing.com South Africa
Benchmark maintains Buy rating on Bio-Techne stock amid tariff impact - Investing.com India
Stochastic Optical Reconstruction Miicroscope Market Size, - openPR.com
3.28%
1.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):